While our cell line-based analyses provide preliminary functional evidence for methylation-driven silencing of SPARC, the need to incorporate a comprehensive panel of primary fibroblasts derived from both IPF patients and healthy donors will be essential to assess interindividual variability and confirm reproducibility of these findings. This evidence concerns the gene SPARC and idiopathic pulmonary fibrosis.